Premium
Functional interaction between pre‐synaptic α6β2 ‐containing nicotinic and adenosine A 2A receptors in the control of dopamine release in the rat striatum
Author(s) -
Garção P,
Szabó E C,
Wopereis S,
Castro A A,
Tomé Â R,
Prediger R D,
Cunha R A,
Agostinho P,
Köfalvi A
Publication year - 2013
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.12234
Subject(s) - nicotine , nicotinic agonist , dopamine , pharmacology , dopaminergic , agonist , chemistry , nicotinic antagonist , neuroscience , medicine , receptor , biology
Background and Purpose Pre‐synaptic nicotinic ACh receptors ( nAChRs ) and adenosine A 2A receptors ( A 2A Rs ) are involved in the control of dopamine release and are putative therapeutic targets in P arkinson's disease and addiction. Since A 2A Rs have been reported to interact with nAChRs , here we aimed at mapping the possible functional interaction between A 2A Rs and nAChRs in rat striatal dopaminergic terminals. Experimental Approach We pharmacologically characterized the release of dopamine and defined the localization of nAChR subunits in rat striatal nerve terminals in vitro and carried out locomotor behavioural sensitization in rats in vivo . Key Results In striatal nerve terminals, the selective A 2A R agonist CGS 21680 inhibited, while the A 2A R antagonist ZM 241385 potentiated the nicotine‐stimulated [ 3 H ]dopamine ([ 3 H]DA) release. Upon blockade of the α6 subunit‐containing nAChRs , the remaining nicotine‐stimulated [ 3 H ]DA release was no longer modulated by A 2A R ligands. In the locomotor sensitization experiments, nicotine enhanced the locomotor activity on day 7 of repeated nicotine injection, an effect that no longer persisted after 1 week of drug withdrawal. Notably, ZM 241385‐injected rats developed locomotor sensitization to nicotine already on day 2, which remained persistent upon nicotine withdrawal. Conclusions and Implications These results provide the first evidence for a functional interaction between nicotinic and adenosine A 2A R in striatal dopaminergic terminals, with likely therapeutic consequences for smoking, Parkinson's disease and other dopaminergic disorders.